Erelel, MustafaKaskal, MertAkbal-Dağıstan, Özlemİşsever, HalimErtürk, Aybige2021-11-082021-11-082021Erelel M, Kaskal M, Akbal-Dagistan O, Issever H, Dagistanli AS, Balkanci H, Oguz MS, Qarayeva A, Culha M, Erturk A, Basarir NS, Sahin G, Uresin AY, Araman AO, Medetalibeyoglu A, Tukek T, Oncul MO, Yildiz-Pekoz A. Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial. Pharmaceutics. 2021; 13(11):1768. https://doi.org/10.3390/pharmaceutics131117681999-4923https://doi.org/10.3390/pharmaceutics13111768https://hdl.handle.net/20.500.12713/2200In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group”; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.eninfo:eu-repo/semantics/openAccessAnti-coagulanCOVID-19Low-Molecular-Weight HeparinPulmonarySoft-mist İnhalerArticle1311113WOS:000727143300001Q110.3390/pharmaceutics13111768